Company intelligence / Profile preview

Engineered Tissue Solutions

Rolla, Missouri, United Statesengineeredtissue.com ↗

Ownership: Private
Development stage: Commercial

Overview

Mirragen® and MirraSurg are FDA-cleared bioactive glass wound matrices shown to be safe and effective in clinical trials for a variety of acute and chronic wound types. In randomized controlled trials for diabetic foot ulcers and other complex wounds, zero index wound infections were reported versus standard of care. The products are fully synthetic with no animal or human tissue components.

Therapeutic areas: Dermatology
Modalities: DeviceSynthetic skin substitute (Bioactive glass matrix)Biomaterial-based therapy
Industry: Therapeutic Medical Devices

Drug pipeline

2 assets

Mirragen

Commercial

Indications: Chronic wounds, Diabetic foot ulcers

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Engineered Tissue Solutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Engineered Tissue Solutions.

Explore the full profile